{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-22-000149","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.213627+00:00","generated_at":"2026-06-21T05:24:28.498676+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Evolus amends Daewoong supply pact: exits Russia, revamps Europe pricing","bullets":["Evolus exits Russia; all rights to neurotoxin distribution revert to Daewoong.","European pricing changed from fixed transfer price to net-sales-based price with quarterly true-up.","Transfer price renegotiated annually; floor price per vial set.","Evolus must meet launch schedule and reporting obligations; failure allows Daewoong to revert pricing.","Parties to cooperate on transferring Russia regulatory materials to Daewoong."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-22-000149","json":"https://secwatch.observer/filing/0001570562-22-000149.json","markdown":"https://secwatch.observer/filing/0001570562-22-000149.md","text":"https://secwatch.observer/filing/0001570562-22-000149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000149/0001570562-22-000149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000149/eols-20221212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:24:28.498676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"789d1d0b41906534d9cf5750c850761f4419904a","claim":"Evolus, Inc. amended Fourth Amendment to License and Supply Agreement with Daewoong Pharmaceuticals Co., Ltd. (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, Evolus, Inc., a Delaware corporation (the “Company”), and Daewoong Pharmaceuticals Co., Ltd., a corporation organized and existing under the laws of the Republic of Korea (“Daewoong”) entered into a Fourth Amendment (the “Fourth Amendment”) to that certain License and Supply Agreement (the “Supply Agreement”), originally dated September 30, 2013, as amended.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000149/0001570562-22-000149-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Daewoong Pharmaceuticals Co., Ltd."},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}